Heart drugs that affect bone

Trends in Endocrinology and Metabolism

Volumn 23, Issue 4, 2012, Pages 163-168

  Walsh, Jennifer S ^a   Newman, Chris ^a   Eastell, Richard ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; LOOP DIURETIC AGENT; MEVALONIC ACID; MEVINOLIN; ORGANIC NITRATE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PRAVASTATIN; PROPRANOLOL; SIMVASTATIN; THIAZIDE DIURETIC AGENT; WARFARIN;

ANGINA PECTORIS; ATHEROSCLEROSIS; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONGESTIVE HEART FAILURE; FRACTURE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LOW DRUG DOSE; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84858746623     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.10.002     Document Type: Review

References (85)

1. Yadav V.K., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.
2. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif. Tissue Int. 2004, 75:451-461.
3. Wimalawansa S.J. Nitric oxide and bone. Ann. N. Y. Acad. Sci. 2010, 1192:391-403.
4. Mundy G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
5. Maeda T., et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 2001, 280:874-877.
6. Sugiyama M., et al. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 2000, 271:688-692.
7. Woo J.T., et al. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J. Bone Miner. Res. 2000, 15:650-662.
8. Staal A., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 2003, 18:88-96.
9. Oxlund H., et al. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif. Tissue Int. 2001, 69:299-304.
10. de Vries F., et al. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int. J. Epidemiol. 2006, 35:1301-1308.
11. Wang P.S., et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000, 283:3211-3216.
12. Schoofs M.W., et al. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J. Bone Miner. Res. 2004, 19:1525-1530.
13. Chan K.A., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185-2188.
14. Rejnmark L., et al. Hip fracture risk in statin users - a population-based Danish case-control study. Osteoporos. Int. 2004, 15:452-458.
15. LaCroix A.Z., et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann. Intern. Med. 2003, 139:97-104.
16. Reid I.R., et al. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial - secondary analysis of a randomized controlled trial. Bone 2005, 37:190-191.
17. Reid I.R., et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001, 357:509-512.
18. Chuengsamarn S., et al. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 2010, 46:1011-1015.
19. Rejnmark L., et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J. Bone Miner. Res. 2004, 19:737-744.
20. Berthold H.K., et al. Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. Osteoporos. Int. 2004, 15:459-467.
21. Uzzan B., et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.
22. Gutierrez G.E., et al. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos. Int. 2006, 17:1033-1042.
23. Moore R.E., et al. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 1993, 23:301-315.
24. Reid I.R. Effects of beta-blockers on fracture risk. J. Musculoskelet. Neuronal. Interact. 2008, 8:105-110.
25. Bonnet N., et al. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J. Pharmacol. Exp. Ther. 2006, 318:1118-1127.
26. Pasco J.A., et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res. 2004, 19:19-24.
27. Yang S., et al. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2011, 48:451-455.
28. de Vries F., et al. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif. Tissue Int. 2007, 80:69-75.
29. Rejnmark L., et al. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens. 2006, 24:581-589.
30. Levasseur R., et al. Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J. Am. Geriatr. Soc. 2005, 53:550-552.
31. Solomon D.H., et al. The risk of fractures in older adults using anti-hypertensive medications. J. Bone Miner. Res. 2011, 26:1561-1567.
32. Reid I.R., et al. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. 2005, 20:613-618.
33. Bonnet N., et al. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007, 40:1209-1216.
34. Reid I.R., et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2005, 90:5212-5216.
35. Ray W.A., et al. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989, 1:687-690.
36. Felson D.T., et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991, 265:370-373.
37. LaCroix A.Z., et al. Thiazide diuretic agents and the incidence of hip fracture. N. Engl. J. Med. 1990, 322:286-290.
38. Nguyen T.V., et al. Risk factors for osteoporotic fractures in elderly men. Am. J. Epidemiol. 1996, 144:255-263.
39. Schoofs M.W., et al. Thiazide diuretics and the risk for hip fracture. Ann. Intern. Med. 2003, 139:476-482.
40. Cauley J.A., et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 1993, 118:666-673.
41. Heidrich F.E., et al. Diuretic drug use and the risk for hip fracture. Ann. Intern. Med. 1991, 115:1-6.
42. Wasnich R.D., et al. Thiazide effect on the mineral content of bone. N. Engl. J. Med. 1983, 309:344-347.
43. Morton D.J., et al. Thiazides and bone mineral density in elderly men and women. Am. J. Epidemiol. 1994, 139:1107-1115.
44. Orwoll E.S., et al. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 1996, 124:187-196.
45. Sigurdsson G., Franzson L. Increased bone mineral density in a population-based group of 70-year-old women on thiazide diuretics, independent of parathyroid hormone levels. J. Intern. Med. 2001, 250:51-56.
46. Olmos J.M., et al. Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment. Maturitas 2010, 65:396-402.
47. Adland-Davenport P., et al. Thiazide diuretics and bone mineral content in postmenopausal women. Am. J. Obstet. Gynecol. 1985, 152:630-634.
48. Ooms M.E., et al. Determinants of bone mineral density and risk factors for osteoporosis in healthy elderly women. J. Bone Miner. Res. 1993, 8:669-675.
49. Bolland M.J., et al. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos. Int. 2007, 18:479-486.
50. LaCroix A.Z., et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2000, 133:516-526.
51. Ott S.M., et al. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos. Int. 2008, 19:1315-1322.
52. Dawson-Hughes B., et al. Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women. J. Clin. Endocrinol. Metab. 2009, 94:96-102.
53. Ralston S.H., et al. Nitric oxide: a cytokine-induced regulator of bone resorption. J. Bone Miner. Res. 1995, 10:1040-1049.
54. van't Hof R.J., Ralston S.H. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J. Bone Miner. Res. 1997, 12:1797-1804.
55. Aguirre J., et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am. J. Pathol. 2001, 158:247-257.
56. Armour K.E., et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001, 142:760-766.
57. Wimalawansa S.J., et al. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996, 18:301-304.
58. Wimalawansa S.J., et al. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone 1997, 21:275-280.
59. Rejnmark L., et al. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J. Bone Miner. Res. 2006, 21:1811-1817.
60. Pouwels S., et al. Use of organic nitrates and the risk of hip fracture: a population-based case-control study. J. Clin. Endocrinol. Metab. 2010, 95:1924-1931.
61. Jamal S.A., et al. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos. Int. 2009, 20:737-744.
62. Jamal S.A., et al. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J. Bone Miner. Res. 1998, 13:1755-1759.
63. Wimalawansa S., et al. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. J. Bone Miner. Res. 2000, 15:1119-1125.
64. Jamal S.A., et al. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J. Bone Miner. Res. 2004, 19:1512-1517.
65. Wimalawansa S.J., et al. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J. Clin. Endocrinol. Metab. 2009, 94:3356-3364.
66. Jamal S.A., et al. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA 2011, 305:800-807.
67. Rejnmark L., et al. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J. Intern. Med. 2005, 257:176-184.
68. Rejnmark L., et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J. Bone Miner. Res. 2006, 21:163-170.
69. Rejnmark L., et al. Fracture risk in patients treated with loop diuretics. J. Intern. Med. 2006, 259:117-124.
70. Tromp A.M., et al. Predictors of fractures in elderly women. Osteoporos. Int. 2000, 11:134-140.
71. Carbone L.D., et al. Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch. Intern. Med. 2009, 169:132-140.
72. Lim L.S., et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch. Intern. Med. 2008, 168:735-740.
73. Hauschka P.V., et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol. Rev. 1989, 69:990-1047.
74. Haffa A., et al. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J. Bone Miner. Res. 2000, 15:872-878.
75. Simon R.R., et al. Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb. Res. 2002, 105:353-358.
76. Sugiyama T., et al. Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli. J. Endocrinol. 2007, 194:213-222.
77. Binkley N., et al. Vitamin K deficiency from long-term warfarin anticoagulation does not alter skeletal status in male rhesus monkeys. J. Bone Miner. Res. 2007, 22:695-700.
78. Menon R.K., et al. Impaired carboxylation of osteocalcin in warfarin-treated patients. J. Clin. Endocrinol. Metab. 1987, 64:59-61.
79. Jamal S.A., et al. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 1998, 128:829-832.
80. Woo C., et al. Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J. Am. Geriatr. Soc. 2008, 56:1171-1176.
81. Gage B.F., et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch. Intern. Med. 2006, 166:241-246.
82. Philip W.J., et al. Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 1995, 88:635-640.
83. Sato Y., et al. Long-term oral anticoagulation therapy and the risk of hip fracture in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Cerebrovasc. Dis. 2010, 29:73-78.
84. Rosen H.N., et al. Vitamin K and maintenance of skeletal integrity in adults. Am. J. Med. 1993, 94:62-68.
85. Rejnmark L., et al. Fracture risk in patients treated with amiodarone or digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporos. Int. 2007, 18:409-417.